Loading
A phase 3 trial of SHR-A2009, Aumolertinib in non-small-cell lung cancer and small-cell lung cancer, run by Suzhou Suncadia Biopharmaceuticals Co., Ltd., now recruiting.
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC is a phase 3 interventional study registered as NCT07183189 by Suzhou Suncadia Biopharmaceuticals Co., Ltd., with 576 participants planned, started 2025-10-30 and due to reach its primary completion in 2032-11. Interventions recorded: SHR-A2009 ; Aumolertinib, Aumolertinib. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares SHR-A2009, Jiangsu Hengrui Pharmaceuticals, EGFR-mutated non-small-cell lung cancer, Non-small-cell lung cancer.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares SHR-A2009, Aumolertinib, Jiangsu Hengrui Pharmaceuticals.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.
Shares Aumolertinib, EGFR-mutated non-small-cell lung cancer, Small-molecule kinase inhibitors.